BDParib 200mg Tablet : View Rucaparib Use, Dosage - USD850.00

Rucaparib, an oral, small molecule, poly (ADP-ribose) polymerase (PARP) inhibitor, is used in the treatment of ovarian cancer and prostate cancer. For the treatment of ovarian cancer, it is commonly referred to as monotherapy. Many other drug manufacturers have introduced this medicine under their own brand names after the first launch of brand name medicine "Rubraca™" with the composition Rucaparib

BDR Pharmaceuticals has marketed it as "BDParib 200mg Tablet."

Packing - 60 Tablets in a Pack

BDParib 200mg (Rucaparib) has anti-cancer properties, it induces synthetic lethality in homologous recombination deficient (HRD) tumors (e.g. BRCA mutation). BDParib significantly improved progression-free survival in patients

The dosage recommendation of BDParib tablet for cancer patients is 600 mg twice a day with or without the food.

BDParib 200mg has several adverse effects that must be addressed throughout the conversation. Consult your doctor for further information.